U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H27N.ClH
Molecular Weight 329.907
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUDIPINE HYDROCHLORIDE

SMILES

Cl.CC(C)(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=USUUKNCFNKZGEY-UHFFFAOYSA-N
InChI=1S/C21H27N.ClH/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19;/h4-13H,14-17H2,1-3H3;1H

HIDE SMILES / InChI

Description

Budipine is an antiparkinsonian drug, which was developed by Byk Gulden (now Takeda) for the treatment of Parkinson's disease. The drug has multiple mechanisms of action: it was found to interfere with dopamine biosynthesis, mainly by inhibiting MAO-B enzyme and stimulating aromatic L-amino acid decarboxylase. Also the drug inhibits the dopamine re-uptake and has weak affinity to NMDA and muscarinic receptors. Budipine passes the blood-brain barrier, is metabolized by hydroxylation, and is excreted by both in urine and feces within 24 h.

CNS Activity

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Amine oxidase [flavin-containing] B
11
Target ID: P27338
Gene ID: 4129.0
Gene Symbol: MAOB
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 5.0 µM [IC50]
Sodium-dependent dopamine transporter
43
Target ID: Q01959
Gene ID: 6531.0
Gene Symbol: SLC6A3
Target Organism: Homo sapiens (Human)
Blocker
555
 11.0 µM [IC50]
Aromatic-L-amino-acid decarboxylase
5
Target ID: P20711
Gene ID: 1644.0
Gene Symbol: DDC
Target Organism: Homo sapiens (Human)
Activator
1447
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
PARKINSAN

Approved Use

For combination therapy of Parkinson's disease.

Launch Date

1996
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
REVIEW
https://pubmed.ncbi.nlm.nih.gov/16784759/
BUDIPINE plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
20 mg 3 times / day steady-state, oral
Studied dose
Dose: 20 mg, 3 times / day
Route: oral
Route: steady-state
Dose: 20 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3302121/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3302121/
Disc. AE: mental confusion...
AEs leading to
discontinuation/dose reduction:
mental confusion (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3302121/
AEs

AEs

AESignificanceDosePopulation
mental confusion 2 patients
Disc. AE
20 mg 3 times / day steady-state, oral
Studied dose
Dose: 20 mg, 3 times / day
Route: oral
Route: steady-state
Dose: 20 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3302121/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3302121/
PubMed

PubMed

TitleDatePubMed
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
2010-03
A new strategy for antidepressant prescription.
2010
Paradoxical aspects of parkinsonian tremor.
2008-01-30
Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats.
2006-10-30
Budipine in Parkinson's tremor.
2006-10-25
[Diagnosis and therapy of idiopathic Parkinson's disease].
2006-05-15
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
2006-01
Pharmacotherapy of Parkinson's disease in Germany.
2005-08
Efficacy of budipine and placebo in untreated patients with Parkinson's disease.
2005-08
Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats.
2005-07
The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice.
2005-01-07
Synergism between topiramate and budipine in refractory status epilepticus in the rat.
2004-11
Antiapoptotic effects of budipine.
2004-10
Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.
2003-11
Evaluation of possible pro- or antioxidative properties and of the interaction capacity with the microsomal cytochrome P450 system of different NMDA-receptor ligands and of taurine in vitro.
2003-06
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
2003-05-26
[Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].
2002-05-06
Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.
2002-05
Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies.
2001-09
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.
2001-08
Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration.
2001-06
Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings.
2001-05
Non-dopaminergic drug treatment of Parkinson's disease.
2001-04
[Monotherapy of Parkinson's disease with budipine. A double blind comparison with amantadine].
2001-02
Workshop IV: drug treatment guidelines for the long-term management of Parkinson's disease.
2000-09
[Synthesis, physical-chemical properties and pharmacologically-oriented screening studies on budipine and related 4,4-diphenylpiperidines].
1984
Patents

Patents

JP2007518755A
2

Sample Use Guides

In Vivo Use Guide
The dosage is determined individually. The treatment should start with 3 times daily 10 mg budipine hydrochloride. If necessary, the daily dose should be increased at the earliest after 1 week to 3 x 20 mg budipine hydrochloride or 2 x 30 mg budipine hydrochloride.
Route of Administration: Oral
In Vitro Use Guide
10(-7), 10(-8), 10(-9) mol/l of budipine significantly reduced release of TNF-alpha and Il-6 in PBMC and decreased apoptotic cell death after 50 hours and 74 hours in the SH-SY 5Y cells.
Name Type Language
PARKINSAN
Preferred Name English
BUDIPINE HYDROCHLORIDE
MI   WHO-DD  
Common Name English
BUDIPINE HYDROCHLORIDE [MI]
Common Name English
1-TERT-BUTYL-4,4-DIPHENYLPIPERIDINIUM CHLORIDE
Systematic Name English
Budipine Hydrochloride [WHO-DD]
Common Name English
Code System Code Type Description
MERCK INDEX
m2747
Created by admin on Mon Mar 31 18:15:12 GMT 2025 , Edited by admin on Mon Mar 31 18:15:12 GMT 2025
PRIMARY Merck Index
PUBCHEM
3030419
Created by admin on Mon Mar 31 18:15:12 GMT 2025 , Edited by admin on Mon Mar 31 18:15:12 GMT 2025
PRIMARY
FDA UNII
NBF4Q9307Q
Created by admin on Mon Mar 31 18:15:12 GMT 2025 , Edited by admin on Mon Mar 31 18:15:12 GMT 2025
PRIMARY
EPA CompTox
DTXSID60979889
Created by admin on Mon Mar 31 18:15:12 GMT 2025 , Edited by admin on Mon Mar 31 18:15:12 GMT 2025
PRIMARY
EVMPD
SUB35026
Created by admin on Mon Mar 31 18:15:12 GMT 2025 , Edited by admin on Mon Mar 31 18:15:12 GMT 2025
PRIMARY
RXCUI
236892
Created by admin on Mon Mar 31 18:15:12 GMT 2025 , Edited by admin on Mon Mar 31 18:15:12 GMT 2025
PRIMARY RxNorm
SMS_ID
100000128225
Created by admin on Mon Mar 31 18:15:12 GMT 2025 , Edited by admin on Mon Mar 31 18:15:12 GMT 2025
PRIMARY
CAS
63661-61-0
Created by admin on Mon Mar 31 18:15:12 GMT 2025 , Edited by admin on Mon Mar 31 18:15:12 GMT 2025
PRIMARY
ECHA (EC/EINECS)
264-388-5
Created by admin on Mon Mar 31 18:15:12 GMT 2025 , Edited by admin on Mon Mar 31 18:15:12 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of BUDIPINE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966